Elias Jabbour, M.D.

Peer-Reviewed Articles

1. Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol 182(3):442-444, 2018. e-Pub 2017. PMID: 28616864.
2. Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia. Am J Clin Oncol 41(3):213-217, 2018. e-Pub 2015. PMID: 26580245.
3. Kanagal-Shamanna R, Loghavi S, DiNardo CD, Medeiros LJ, Garcia-Manero G, Jabbour E, Routbort MJ, Luthra R, Bueso-Ramos CE, Khoury JD. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 102(10):1661-1670, 2017. e-Pub 2017. PMID: 28659335.
4. Short NJ, Jabbour E. Yes, treatment for CML should continue indefinitely. Clin Adv Hematol Oncol 15(6):489-492, 2017. PMID: 28749909.
5. Kantarjian H, Jabbour E, Topp MS. Blinatumomab for Acute Lymphoblastic Leukemia. N Engl J Med 376(23):e49, 2017. PMID: 28591537.
6. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation. Am J Hematol 92(4):331-337, 2017. e-Pub 2017. PMID: 28052408.
7. Yilmaz M, Kantarjian H, Jabbour E. Treatment of acute lymphoblastic leukemia in older adults: now and the future. Clin Adv Hematol Oncol 15(4):266-274, 2017. PMID: 28591103.
8. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129(10):1275-1283, 2017. e-Pub 2016. PMID: 28003274.
9. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol 92(3):238-243, 2017. e-Pub 2017. PMID: 28006851.
10. Pemmaraju N, Kantarjian H, Jorgensen JL, Jabbour E, Jain N, Thomas D, O'Brien S, Wang X, Huang X, Wang SA, Konopleva M, Konoplev S, Kadia T, Garris R, Pierce S, Garcia-Manero G, Cortes J, Ravandi F. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol 92(3):279-285, 2017. e-Pub 2017. PMID: 28052371.
11. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer 123(3):426-435, 2017. e-Pub 2016. PMID: 27657543.
12. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer 123(3):459-467, 2017. e-Pub 2016. PMID: 27696391.
13. Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer 123(4):629-637, 2017. e-Pub 2016. PMID: 27741352.
14. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer 123(4):609-616, 2017. e-Pub 2016. PMID: 27763690.
15. Pinnix CC, Chi L, Jabbour E, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia. Am J Hematol 92(2):155-160, 2017. e-Pub 2016. PMID: 27874212.
16. Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, Zweidler-McKay P, Lu X, Fawcett G, Wang SA, Konoplev S, Harvey RC, Chen IM, Payne-Turner D, Valentine M, Thomas D, Garcia-Manero G, Ravandi F, Cortes J, Kornblau S, O'Brien S, Pierce S, Jorgensen J, Shaw KR, Willman CL, Mullighan CG, Kantarjian H, Konopleva M. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood 129(5):572-581, 2017. e-Pub 2016. PMID: 27919910.
17. Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer 123(2):294-302, 2017. e-Pub 2016. PMID: 27602508.
18. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol 92(1):7-11, 2017. e-Pub 2016. PMID: 27673440.
19. Jain P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, Patel K, Pierce S, Garcia-Manero G, Borthakur G, Ravandi F, O'Brien S, Cortes J. Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). Am J Hematol 92(1):E3-E4, 2017. e-Pub 2016. PMID: 27727470.
20. Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Am J Hematol 91(12):1221-1226, 2016. e-Pub 2016. PMID: 27474808.
21. Sasaki K, Jabbour E, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer 122(23):3650-3656, 2016. e-Pub 2016. PMID: 27479888.
22. Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 122(24):3812-3820, 2016. e-Pub 2016. PMID: 27508525.
23. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer 122(22):3484-3491, 2016. e-Pub 2016. PMID: 27463065.
24. Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver N, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk 16(11):616-624, 2016. e-Pub 2016. PMID: 27601000.
25. Paul S, Kantarjian H, Jabbour E. Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc 91(11):1645-1666, 2016. PMID: 27814839.
26. Short NJ, Jabbour E. Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive? Intensive treatment is the best treatment for these patients. Clin Adv Hematol Oncol 14(11):892-894, 2016. PMID: 27930640.
27. Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer 122(21):3336-3343, 2016. e-Pub 2016. PMID: 27509035.
28. Huang L, Wang SA, Konoplev S, Bueso-Ramos CE, Thakral B, Miranda RN, Jabbour E, Medeiros LJ, Kanagal-Shamanna R. Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report. Medicine (Baltimore) 95(41):e4934, 2016. PMID: 27741105.
29. Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. Am J Hematol 91(8):800-5, 2016. e-Pub 2016. PMID: 27169385.
30. Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - A propensity score analysis. Haematologica 101(8):e324-7, 2016. e-Pub 2016. PMID: 27175025.
31. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol 91(8):819-23, 2016. e-Pub 2016. PMID: 27178680.
32. Hoehn D, Cortes JE, Medeiros LJ, Jabbour E, Hidalgo JE, Kanagal-Shamanna R, Bueso-Ramos CE. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. Clin Lymphoma Myeloma Leuk 16 Suppl:S86-92, 2016. PMID: 27521332.
33. Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128(4):504-7, 2016. e-Pub 2016. PMID: 27235138.
34. Short NJ, Kantarjian HM, Jabbour E, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol 91(4):385-9, 2016. e-Pub 2016. PMID: 26800008.
35. Vitale C, Jabbour E, Lu X, Yabe M, Kanagal Shamanna R, Daver N, Pemmaraju N, Bueso-Ramos CE, Takahashi K. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. Am J Hematol 91(4):E274-6, 2016. e-Pub 2016. PMID: 26798971.
36. Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer 122(12):1871-9, 2016. e-Pub 2016. PMID: 26990290.
37. Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Ali NA, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA, MDS Clinical Research Consortium. The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes at the Time of Hypomethylating Agent Failure. Haematologica 101(6):e224-7, 2016. e-Pub 2016. PMID: 26992944.
38. Jabbour E, Kantarjian H. Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma. Lancet 387(10036):2360-1, 2016. e-Pub 2016. PMID: 27080497.
39. Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood 127(15):1863-9, 2016. e-Pub 2016. PMID: 26747249.
40. Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Nogueras Gonzalez G, Verstovsek S, Borthakur G, Wierda W, Kadia T, Dellasala S, Pierce S, Ravandi F, O'Brien S, Cortes J. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol 173(1):114-26, 2016. e-Pub 2016. PMID: 26846160.
41. Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR, ONTIME study investigators. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol 17(4):496-508, 2016. e-Pub 2016. PMID: 26968357.
42. Huang L, Garcia-Manero G, Jabbour E, Goswami M, Routbort MJ, Medeiros LJ, Jorgensen JL, Wang SA. Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents. J Clin Pathol. e-Pub 2016. PMID: 27083210.
43. Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 127(10):1269-75, 2016. e-Pub 2016. PMID: 26729897.
44. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget 7(12):14172-87, 2016. e-Pub 2016. PMID: 26871476.
45. Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk 16(3):163-168.e2, 2016. e-Pub 2015. PMID: 26752456.
46. Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 16(3):139-45, 2016. e-Pub 2015. PMID: 26775883.
47. Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver N, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk 16(3):152-62, 2016. e-Pub 2015. PMID: 26796981.
48. Jabbour EJ. A Man With Pre-B-Cell, CD20-Negative ALL. Clin Adv Hematol Oncol 14(3 Suppl 4):10-4, 2016. PMID: 27007407.
49. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol 172(3):392-400, 2016. e-Pub 2015. PMID: 26492205.
50. Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour E, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS, MDS Clinical Research Consortium. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res 41:43-7, 2016. e-Pub 2015. PMID: 26777537.
51. George B, Kantarjian H, Jabbour E, Jain N. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy 8(2):135-43, 2016. e-Pub 2016. PMID: 26780449.
52. DiNardo CD, Garcia-Manero G, Pierce S, Nazha A, Bueso-Ramos C, Jabbour E, Ravandi F, Cortes J, Kantarjian H. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol 91(2):227-32, 2016. PMID: 26799610.
53. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol 91(2):252-65, 2016. PMID: 26799612.
54. Iacobucci I, Li Y, Roberts KG, Dobson SM, Kim JC, Payne-Turner D, Harvey RC, Valentine M, McCastlain K, Easton J, Yergeau D, Janke LJ, Shao Y, Chen IM, Rusch M, Zandi S, Kornblau SM, Konopleva M, Jabbour E, Paietta EM, Rowe JM, Pui CH, Gastier-Foster J, Gu Z, Reshmi S, Loh ML, Racevskis J, Tallman MS, Wiernik PH, Litzow MR, Willman CL, McPherson JD, Downing JR, Zhang J, Dick JE, Hunger SP, Mullighan CG. Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell 29(2):186-200, 2016. PMID: 26859458.
55. Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer 122(2):238-48, 2016. e-Pub 2015. PMID: 26479889.
56. McGarry LJ, Chen YJ, Divino V, Pokras S, Taylor CR, Munakata J, Nieset CC, Huang H, Jabbour E, Malone DC. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Curr Med Res Opin 32(2):1-11, 2016. e-Pub 2015. PMID: 26566171.
57. Chamseddine AN, Jabbour E, Kantarjian HM, Bohannan ZS, Garcia-Manero G. Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. Curr Oncol Rep 18(1):4, 2016. PMID: 26700507.
58. Jabbour E. Chronic myeloid leukemia: First-line drug of choice. Am J Hematol 91(1):59-66, 2016. PMID: 26769227.
59. Dahl J, Marx K, Jabbour E. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia. Expert Rev Hematol 9(4):329-34, 2016. e-Pub 2016. PMID: 26783163.
60. Sanford D, Kantarjian H, Skinner J, Jabbour E, Cortes J. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor. Haematologica 100(12):e494-5, 2015. e-Pub 2015. PMID: 26341741.
61. Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour E, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res 39(12):1367-74, 2015. e-Pub 2015. PMID: 26547258.
62. Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines. Clin Lymphoma Myeloma Leuk 15(12):797-802.e1, 2015. e-Pub 2015. PMID: 26603185.
63. Yilmaz M, Jabbour E. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia. Semin Oncol 42(6):876-86, 2015. e-Pub 2015. PMID: 26615132.
64. Jabbour E. Use of PCR testing in chronic myeloid leukemia. Clin Adv Hematol Oncol 13(12):808-10, 2015. PMID: 27058845.
65. Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour E, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. J Clin Oncol 33(33):3953-60, 2015. e-Pub 2015. PMID: 26324368.
66. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 16(15):1547-55, 2015. e-Pub 2015. PMID: 26432046.
67. Yilmaz M, Richard S, Jabbour E. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Ther Adv Hematol 6(5):253-61, 2015. PMID: 26425338.
68. Sanford D, DiNardo CD, Tang G, Cortes JE, Verstovsek S, Jabbour E, Ravandi F, Kantarjian H, Garcia-Manero G. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk 15(9):556-62, 2015. e-Pub 2015. PMID: 26141213.
69. Mattiuzzi G, Yilmaz M, Kantarjian H, Borthakur G, Konopleva M, Jabbour E, Brown Y, Pierce S, Cortes J. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. J Infect Chemother 21(9):663-7, 2015. e-Pub 2015. PMID: 26141814.
70. Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes J. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol 2(9):e376-e383, 2015. PMID: 26436130.
71. Shen Q, Ouyang J, Tang G, Jabbour E, Garcia-Manero G, Routbort M, Konoplev S, Bueso-Ramos C, Medeiros LJ, Jorgensen JL, Wang SA. Flow Cytometry Immunophenotypic Findings in Chronic Myelomonocytic Leukemia and Its Utility in Monitoring Treatment Response. Eur J Haematol 95(2):168-76, 2015. e-Pub 2015. PMID: 25354960.
72. Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol 170(4):590-3, 2015. e-Pub 2015. PMID: 25716073.
73. Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson B, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1405-12, 2015. e-Pub 2015. PMID: 25840338.
74. Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov Z. Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. Am J Hematol 90(8):752-3, 2015. e-Pub 2015. PMID: 25850565.
75. Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer 121(15):2517-28, 2015. e-Pub 2015. PMID: 25891003.
76. Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. Haematologica 100(8):1058-63, 2015. e-Pub 2015. PMID: 26088933.
77. Patel KP, Newberry KJ, Luthra R,Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 126(6):790-7, 2015. e-Pub 2015. PMID: 26124496.
78. Bryan JC, Jabbour E. Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. Drugs Aging 32(8):623-37, 2015. PMID: 26286093.
79. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F,Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 100(7):927-34, 2015. e-Pub 2015. PMID: 25682597.
80. Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, Ferrajoli A, Konopleva M, Burger J, Huang X, Wang X, Pierce S, Brandt M, Feliu J, Cortes J, Kantarjian H. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer 121(14):2375-82, 2015. e-Pub 2015. PMID: 25809968.
81. Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE. A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica 100(7):898-904, 2015. e-Pub 2015. PMID: 25887498.
82. Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res 21(12):2704-14, 2015. e-Pub 2015. PMID: 25724525.
83. Yilmaz M, Abaza Y, Jabbour E. Selecting the best frontline treatment in chronic myeloid leukemia. Curr Hematol Malig Rep 10(2):145-57, 2015. PMID: 25921387.
84. Jabbour E, Kantarjian H, Cortes J. Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm. Clin Lymphoma Myeloma Leuk 15(6):323-334, 2015. e-Pub 2015. PMID: 25971713.
85. Jabbour E, Garcia-Manero G. Deacetylase Inhibitors for the Treatment of Myelodysplastic Syndromes. Leuk Lymphoma 56(5):1-26, 2015. e-Pub 2015. PMID: 25058371.
86. Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian HM, Estrov Z. Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol 169(4):595-7, 2015. e-Pub 2014. PMID: 25413673.
87. Daver N, Thomas D, Ravandi F, Cortes J, Garris R,Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Haematologica 100(5):653-61, 2015. e-Pub 2015. PMID: 25682595.
88. Cabrero M, Jabbour E, Ravandi F, Bohannan Z, Pierce S, Kantarjian HM, Garcia-Manero G. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up. Leuk Res 39(5):520-4, 2015. e-Pub 2015. PMID: 25828745.
89. Mace ML, Dahl J, Jabbour E. Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?. Expert Opin Pharmacother 16(7):999-1007, 2015. e-Pub 2015. PMID: 25840461.
90. Chen Y, Estrov Z, Pierce S, Qiao W, Borthakur G, Ravandi F, Kadia T, Brandt M, O'Brien S, Jabbour E, Garcia-Manero G, Cortes J, Beran M. Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma 56(4):1-8, 2015. e-Pub 2014. PMID: 25048874.
91. Sanford DS, Kantarjian H, O'Brien S, Jabbour E, Cortes J, Ravandi F. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther 15(4):365-73, 2015. e-Pub 2015. PMID: 25764322.
92. Ohanian M, Kantarjian H, Guy D, Thomas D, Jabbour E, O'Brien S. Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Expert Opin Biol Ther 15(4):601-11, 2015. PMID: 25775418.
93. Dahl J, Mace M, Kantarjian H, Jabbour E. Blinatumomab for the treatment of adult acute lymphoblastic leukemia. Drugs Today (Barc) 51(4):231-41, 2015. PMID: 26020065.
94. Poon ML, Fox PS, Samuels BI, O'Brien S, Jabbour E, Hsu Y, Gulbis A, Korbling M, Champlin R, Abruzzo LV, Bassett RL, Khouri IF. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. Leuk Lymphoma 56(3):1-5, 2015. e-Pub 2014. PMID: 24913509.
95. Jabbour E, O'Brien S, Huang X, Thomas D, Rytting M, Sasaki K, Cortes J, Garcia-Manero G, Kadia T, Ravandi F, Pierce S, Kantarjian H. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a cd22 monoclonal antibody. Am J Hematol 90(3):193-6, 2015. e-Pub 2015. PMID: 25407953.
96. Jabbour E, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research Consortium. Cancer 121(6):876-82, 2015. e-Pub 2014. PMID: 25410759.
97. Garcia-Manero G, Khoury HJ, Jabbour E, Lancet J, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, Calvo MC, Bohannan Z, List A, Kantarjian H, Komrokji R. A Phase 1 Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate 1 Risk Myelodysplastic Syndromes. Clin Cancer Res 21(5):985-94, 2015. e-Pub 2014. PMID: 25480830.
98. Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S. A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(3):171-6, 2015. e-Pub 2014. PMID: 25441108.
99. Roboz GJ, Khoury HJ, Jabbour E, Session W, Ritchie EK, Miao H, Faderl S, Zheng W, Feldman EJ, Arellano M, Morrison JG, Ravandi F. Phase I trial of SAR103168, a novel multi-kinase inhibitor,in patients with refractory/relapsed acute leukemias or high-risk myelodysplastic syndromes. Leuk Lymphoma 56(2):395-400, 2015. e-Pub 2014. PMID: 24794806.
100. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(2):110-4, 2015. e-Pub 2014. PMID: 25107338.
101. Jabbour E, Garcia-Manero G, Cornelison AM, Cortes JE, Ravandi F, Daver N, Kadia T, Teng A, Kantarjian H. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma 56(2):1-5, 2015. e-Pub 2014. PMID: 24844364.
102. Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 121(4):556-61, 2015. e-Pub 2014. PMID: 25336333.
103. Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II Study of Methotrexate, Vincristine, Pegylated-Asparaginase, and Dexamethasone (MOpAD) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Am J Hematol 90(2):120-4, 2015. e-Pub 2014. PMID: 25368968.
104. Kantarjian H, O'Brien S, Jabbour E, Barnes G, Pathak A, Cortes J. Effectiveness of Homoharringtonine (Omacetaxine Mepesuccinate) for Treatment of Acute Myeloid Leukemia: A Meta-Analysis of Chinese Studies. Clin Lymphoma Myeloma Leuk 15(1):13-21, 2015. e-Pub 2014. PMID: 25458084.
105. Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma 55(12):2879-86, 2014. e-Pub 2013. PMID: 23927391.
106. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour E, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer 120(23):3660-8, 2014. e-Pub 2014. PMID: 25042398.
107. Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL, Gulbis A. BFR (bendamustine, fludarabine and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced risk of myelosuppression and severe graft-versus-host disease. Blood 124(14):2306-12, 2014. e-Pub 2014. PMID: 25145344.
108. Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 14(5):401-10, 2014. e-Pub 2014. PMID: 24875590.
109. Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE. Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 20(10):1618-25, 2014. e-Pub 2014. PMID: 24953017.
110. Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol 89(10):964-8, 2014. e-Pub 2014. PMID: 24990142.
111. Tsimberidou AM, Keating MJ,Jabbour E, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G. A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 14(5):395-400.e1, 2014. e-Pub 2014. PMID: 24637132.
112. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour E, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell 26(3):428-42, 2014. e-Pub 2014. PMID: 25132497.
113. Mathisen MS, Kantarjian HM, Cortes J, Jabbour E. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Rev 28(5):179-187, 2014. e-Pub 2014. PMID: 24984571.
114. Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N,Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res 38(9):1126-9, 2014. e-Pub 2014. PMID: 25047979.
115. DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma 55(8):1925-9, 2014. e-Pub 2014. PMID: 24138309.
116. Quintás-Cardama A, Choi S, Kantarjian H,Jabbour E, Huang X, Cortes J. Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk 14(4):327-334.e8, 2014. e-Pub 2014. PMID: 24594142.
117. Jabbour E, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma 55(7):1451-62, 2014. e-Pub 2013. PMID: 24050507.
118. Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia 28(7):1543-5, 2014. e-Pub 2014. PMID: 24487412.
119. Daver N, Naqvi K, Jabbour E, Kadia T, DiNardo C, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol 89(5):509-16, 2014. e-Pub 2014. PMID: 24458781.
120. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 89(5):547-56, 2014. PMID: 24729196.
121. Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk 14(2):155-162.e1, 2014. e-Pub 2013. PMID: 24332214.
122. Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol 89(4):395-8, 2014. e-Pub 2014. PMID: 24375514.
123. Jabbour E, Ghanem H, Huang X, Ravandi F, Garcia-Manero G, O'Brien S, Faderl S, Pierce S, Choi S, Verstovsek S, Brandt M, Cortes J, Kantarjian H. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk 14(2):93-7, 2014. e-Pub 2013. PMID: 24447728.
124. DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia 28(4):958-61, 2014. e-Pub 2014. PMID: 24492324.
125. Ghanem H, Garcia-Manero G, Faderl S, Ravandi F, Cortes J, Katragadda L, O'Brien S, Daver N, Pierce S, Kadia T, Kantarjian H, Jabbour E. Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Ther Adv Hematol 5(2):29-34, 2014. PMID: 24688752.
126. Jabbour E. Treating myelodysplastic syndrome when hypomethylating agents stop working. Clin Adv Hematol Oncol 12(4):257-9, 2014. PMID: 25003355.
127. Konopleva MY, Walter RB, Faderl SH, Jabbour E, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res 20(8):2226-35, 2014. e-Pub 2014. PMID: 24583795.
128. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28(4):973-5, 2014. e-Pub 2013. PMID: 24157581.
129. Mathisen MS, Kantarjian HM,Jabbour E. Emerging drugs for acute lymphocytic leukemia. Expert Opin Emerg Drugs 19(1):37-50, 2014. e-Pub 2013. PMID: 24354521.
130. Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol 89(3):282-7, 2014. PMID: 24779033.
131. Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer 120(3):373-80, 2014. e-Pub 2013. PMID: 24151050.
132. Bryan J, Kantarjian H, Prescott H, Jabbour E. Clofarabine in the treatment of myelodysplastic syndromes. Expert Opin Investig Drugs 23(2):255-63, 2014. PMID: 24410313.
133. Jabbour E, Ottmann OG, Deininger M, Hochhaus A. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica 99(1):7-18, 2014. PMID: 24425689.
134. Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123(4):494-500, 2014. e-Pub 2013. PMID: 24311723.
135. Mathisen MS, Kantarjian H, Thomas D, O'Brien S, Jabbour E. Acute Lymphoblastic Leukemia (ALL) in Adults: Encouraging Developments on the Way to Higher Cure Rates. Leuk Lymphoma 54(12):2592-600, 2013. e-Pub 2013. PMID: 23547835.
136. Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour E, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88(12):1024-9, 2013. e-Pub 2013. PMID: 23913852.
137. Yilmaz M, Kantarjian H,Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials. Clin Lymphoma Myeloma Leuk 13(6):693-9, 2013. e-Pub 2013. PMID: 24060289.
138. Jabbour E, Lipton JH. A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Clin Lymphoma Myeloma Leuk 13(6):646-56, 2013. e-Pub 2013. PMID: 24095296.
139. Jabbour E, Cortes JE, Kantarjian HM. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther 13(12):1433-52, 2013. PMID: 24236822.
140. Nazha A, Kantarjian H, Jain P, Romo C,Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica 98(11):1686-8, 2013. e-Pub 2013. PMID: 23812943.
141. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G,Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia. Am J Hematol 88(11):961-6, 2013. e-Pub 2013. PMID: 23877926.
142. Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res 37(11):1440-4, 2013. e-Pub 2013. PMID: 23890523.
143. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol 88(10):831-7, 2013. e-Pub 2013. PMID: 23760779.
144. Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour E, Owen K, Stockman PK, Oliver SD. Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML. Clin Lymphoma Myeloma Leuk 13(5):559-67, 2013. e-Pub 2013. PMID: 23763917.
145. Cardenas-Turanzas M, Ravandi-Kashani F, Cortes JE, Jabbour E, Faderl S, Pierce SA, Kantarjian H. Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy. Clin Lymphoma Myeloma Leuk 13(5):579-83, 2013. e-Pub 2013. PMID: 23763918.
146. Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 27(10):2081-3, 2013. e-Pub 2013. PMID: 23774633.
147. Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G. Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine. Clin Lymphoma Myeloma Leuk 13(5):592-6, 2013. e-Pub 2013. PMID: 23790798.
148. Jabbour E, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk 13(5):515-29, 2013. e-Pub 2013. PMID: 23890944.
149. Jabbour E, Cortes J, Ravandi F, O'Brien S, Kantarjian H. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol 50(4):271-83, 2013. e-Pub 2013. PMID: 24246694.
150. Ghanem H, Cornelison AM, Garcia-Manero G, Kantarjian H, Ravandi F, Kadia T, Cortes J, O'Brien S, Brandt M, Borthakur G, Jabbour E. Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S289-94, 2013. e-Pub 2013. PMID: 23969308.
151. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S276-81, 2013. e-Pub 2013. PMID: 23969309.
152. Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien S. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 119(15):2728-36, 2013. e-Pub 2013. PMID: 23633004.
153. Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk 13(4):435-40, 2013. e-Pub 2013. PMID: 23763915.
154. Eghtedar A, Kantarjian H, Jabbour E, O'Brien S, Burton E, Garcia-Manero G, Verstovsek S, Ravandi F, Borthakur G, Konopleva M, Quintas-Cardama A, Cortes J. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 13(4):477-84, 2013. e-Pub 2013. PMID: 23770156.
155. Kantarjian HM, Martinelli G, Jabbour E, Quintás-Cardama A, Ando K, Bay JO, Wei A, Gröpper S, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK, Giagounidis A, SPARK-AML1 Investigators. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer 119(14):2611-9, 2013. e-Pub 2013. PMID: 23605952.
156. Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H. Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes. J Clin Oncol 31(20):2548-53, 2013. e-Pub 2013. PMID: 23733767.
157. Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J. Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities. Blood 121(24):4867-74, 2013. e-Pub 2013. PMID: 23620574.
158. Bhamidipati PK,Jabbour E, Konoplev S, Estrov Z, Cortes J, Daver N. Epstein-Barr Virus-Induced CD30-Positive Diffuse Large B-Cell Lymphoma in a Patient With Mixed-Phenotypic Leukemia Treated With Clofarabine. Clin Lymphoma Myeloma Leuk 13(3):342-6, 2013. e-Pub 2012. PMID: 23246163.
159. Jabbour E, Kantarjian H, Ghanem H, O'Brien S, Quintas-Cardama A, Garcia-Manero G, Cardenas M, Cortes J. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk 13(3):302-6, 2013. e-Pub 2013. PMID: 23318257.
160. Quintás-Cardama A, Jabbour E. Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib. Leuk Res 37(5):487-95, 2013. e-Pub 2013. PMID: 23391518.
161. Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol 88(5):365-9, 2013. e-Pub 2013. PMID: 23512829.
162. Ghanem H, Kantarjian H, Ohanian M,Jabbour E. The role of clofarabine in acute myeloid leukemia. Leuk Lymphoma 54(4):688-98, 2013. e-Pub 2012. PMID: 22957815.
163. Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, Cortes JE, Wierda W, Kantarjian H. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk 13(2):131-8, 2013. e-Pub 2012. PMID: 23260600.
164. Mathisen MS, Kantarjian H, Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, Borthakur G, Cortes JE, Quintás-Cardama A. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Lymphoma Myeloma Leuk 13(2):139-43, 2013. e-Pub 2012. PMID: 23276886.
165. Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol 4(2):103-17, 2013. PMID: 23610618.
166. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol 88(3):198-200, 2013. e-Pub 2013. PMID: 23345254.
167. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 88(1):56-9, 2013. e-Pub 2012. PMID: 23115106.
168. Boumber Y, Kantarjian H, Jorgensen J, Wen S, Faderl S, Castoro R, Autry J, Garcia-Manero G, Borthakur G, Jabbour E, Estrov Z, Cortes J, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia 26(11):2428-31, 2012. e-Pub 2012. PMID: 22665218.
169. Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. Cancer 118(18):4462-70, 2012. e-Pub 2012. PMID: 22252728.
170. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-7, 2012. e-Pub 2012. PMID: 22282348.
171. Jabbour E, Quintás-Cardama A. Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response. Leuk Lymphoma 53(8):1452-60, 2012. e-Pub 2012. PMID: 22273251.
172. Jabbour E, Saglio G, Radich J, Kantarjian H. Adherence to BCR-ABL Inhibitors: Issues for CML Therapy. Clin Lymphoma Myeloma Leuk 12(4):223-9, 2012. e-Pub 2012. PMID: 22633166.
173. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6):1202-9, 2012. e-Pub 2012. PMID: 22718840.
174. Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97(7):1029-35, 2012. e-Pub 2012. PMID: 22271898.
175. Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Ravandi F, Jabbour E, Shan J, Cortes J. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer 118(12):3116-22, 2012. e-Pub 2012. PMID: 22370904.
176. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 157(3):312-20, 2012. e-Pub 2012. PMID: 22360602.
177. Jabbour E, Cortes J, Nazha A, O'Brien S, Quintas-Cardama A, Pierce S, Garcia-Manero G, Kantarjian H. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood 119(19):4524-6, 2012. e-Pub 2012. PMID: 22431574.
178. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13(4):403-11, 2012. e-Pub 2012. PMID: 22357140.
179. Tanaka MF, Kantarjian H, Cortes J, Ohanian M, Jabbour E. Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother 13(6):815-28, 2012. e-Pub 2012. PMID: 22429140.
180. Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukemia: Implications and management strategies. Cancer 118(5):1181-91, 2012. e-Pub 2011. PMID: 22038681.
181. Eghtedar A, Borthakur G, Ravandi F, Jabbour E, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol 87(3):317-8, 2012. e-Pub 2012. PMID: 22228403.
182. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981-7, 2012. e-Pub 2012. PMID: 22228624.
183. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 118(3):722-8, 2012. e-Pub 2011. PMID: 21751197.
184. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, Kelly M, Pierce S, Kantarjian H, Garcia-Manero G. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 87(1):127-9, 2012. e-Pub 2011. PMID: 22072492.
185. Cornelison M, Jabbour E, Welch MA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol 10(1):14-24, 2012. PMID: 22244674.
186. Löwenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, Martinelli G, Amadori S, Berman E, Sonneveld P, Jongen-Lavrencic M, Rigaudeau S, Stockman P, Goudie A, Faderl S, Jabbour E, Kantarjian H. Phase I/II study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 118(23):6030-6, 2011. e-Pub 2011. PMID: 21976672.
187. Quintás-Cardama A, Kantarjian H, Shan J, Jabbour E, Abruzzo LV, Verstovsek S, Garcia-Manero G, O'Brien S, Cortes J. Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer 117(22):5085-93, 2011. e-Pub 2011. PMID: 21523765.
188. Jabbour E, Kantarjian HM, O'Brien S, Shan J, Quintás-Cardama A, Garcia-Manero G, Rios MB, Cortes JE. Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?. J Clin Oncol 29(32):4260-5, 2011. e-Pub 2011. PMID: 21990394.
189. Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S, Garcia-Manero G, Ravandi F, Rios MB, Cortes J. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 118(17):4541-6, 2011. e-Pub 2011. PMID: 21803854.
190. Cortes J, Quintas-Cardama A, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton E, Shan J, Kantarjian H. The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?. Clin Lymphoma Myeloma Leuk 11(5):421-6, 2011. e-Pub 2011. PMID: 21831744.
191. Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, O'Brien S, Cortes J. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 118(16):4353-8, 2011. e-Pub 2011. PMID: 21846902.
192. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G. Implications of discrepancy in morphological diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118(17):4690-3, 2011. e-Pub 2011. PMID: 21868570.
193. Kadia TM, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol 38(5):682-92, 2011. PMID: 21943675.
194. Jabbour E, Parikh SA, Kantarjian H, Cortes J. Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am 25(5):981-95, 2011. e-Pub 2011. PMID: 22054730.
195. Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. J Clin Oncol 29(23):3173-8, 2011. e-Pub 2011. PMID: 21747082.
196. Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J,Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol 86(7):546-9, 2011. e-Pub 2011. PMID: 21509801.
197. Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 118(4):899-902, 2011. e-Pub 2011. PMID: 21622644.
198. Quintás-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Verstovsek S, Shan J, Cortes J. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica 96(6):918-21, 2011. e-Pub 2011. PMID: 21357704.
199. Fullmer A, Kantarjian H, Cortes J, Jabbour E. Dasatinib for the treatment of chronic myeloid leukemia. Expert Rev Hematol 4(3):253-60, 2011. PMID: 21668392.
200. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H, Skikne B. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 29(18):2521-7, 2011. e-Pub 2011. PMID: 21576646.
201. Cornelison AM, Kantarjian H, Cortes J, Jabbour E. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S101-10, 2011. e-Pub 2011. PMID: 22035738.
202. Cornelison AM, Welch MA, Koller C, Jabbour E. Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S111-3, 2011. e-Pub 2011. PMID: 22035739.
203. Champlin R, Jabbour E, Kebriaei P, Anderlini P, Andersson B, de Lima M. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S96-S100, 2011. e-Pub 2011. PMID: 22035758.
204. Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, Gillis K, Woodman RC, Blakesley RE, Giles FJ, Kantarjian HM, Baccarani M. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117(21):5600-6, 2011. e-Pub 2011. PMID: 21467546.
205. Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin Drug Metab Toxicol 7(5):661-72, 2011. e-Pub 2011. PMID: 21500965.
206. Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 117(9):1800-11, 2011. e-Pub 2010. PMID: 21509757.
207. Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE. Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy. Clin Cancer Res 17(7):1674-83, 2011. e-Pub 2011. PMID: 21307148.
208. Al Ameri A, Jabbour E, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Shan J, Pierce S, Cortes J, Kantarjian H. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk 11(2):237-41, 2011. e-Pub 2011. PMID: 21575929.
209. Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer 117(5):897-906, 2011. e-Pub 2010. PMID: 20945321.
210. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 117(6):1236-44, 2011. e-Pub 2010. PMID: 20960519.
211. Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117(13):3641-7, 2011. e-Pub 2010. PMID: 21156844.
212. Mathisen MS, Kantarjian HM, Cortes J,Jabbour E. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica 96(3):347-9, 2011. PMID: 21357713.
213. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood 117(6):1822-7, 2011. e-Pub 2010. PMID: 21030554.
214. Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25(2):201-10, 2011. e-Pub 2010. PMID: 20861918.
215. Fullmer A, Kantarjian H, Cortes J, Jabbour E. New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leuk Lymphoma 52 Suppl 1:81-91, 2011. PMID: 21299461.
216. Al-Kali A, Kantarjian H, Shan J, Bassett R, Quintás-Cardama A, Borthakur G, Jabbour E, Verstovsek S, O'Brien S, Cortes J. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 117(2):327-35, 2011. e-Pub 2010. PMID: 20845478.
217. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, Pierce S, Shan J, Cortes J, O'Brien S. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 116(24):5568-74, 2010. e-Pub 2010. PMID: 20737576.
218. Fullmer A, Kantarjian H, Cortes J, Jabbour E. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. Expert Opin Pharmacother 11(18):3065-72, 2010. e-Pub 2010. PMID: 21073351.
219. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116(22):4422-9, 2010. e-Pub 2010. PMID: 20668231.
220. Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer. e-Pub 2010. PMID: 21117167.
221. Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer 116(19):4580-9, 2010. PMID: 20572037.
222. Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?. Semin Hematol 47(4):344-53, 2010. PMID: 20875551.
223. Yin CC, Cortes J, Galbincea J, Reddy N, Breeden M, Jabbour E, Luthra R, Jones D. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci 101(9):2005-10, 2010. PMID: 20557306.
224. Parikh SA, Kadia T, Jabbour E. Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye. Clin Lymphoma Myeloma Leuk 10(4):301-2, 2010. PMID: 20709669.
225. Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 116(16):3830-4, 2010. PMID: 20564137.
226. Bryan J, Jabbour E, Prescott H, Garcia-Manero G, Issa JP, Kantarjian H. Current and future management options for myelodysplastic syndromes. Drugs 70(11):1381-94, 2010. PMID: 20614946.
227. Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H, Cortes J. Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood 115(26):5428-9, 2010. PMID: 20595523.
228. Bryan J, Jabbour E, Prescott H, Kantarjian H. Thrombocytopenia in patients with myelodysplastic syndromes. Semin Hematol 47(3):274-80, 2010. PMID: 20620439.
229. Jabbour E, Cortes J, Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: An evidence - based review. Core Evid 4:207-13, 2010. e-Pub 2010. PMID: 20694077.
230. Jabbour E, Fullmer A, Cortés JE, Kantarjian H. Clinical Algorithms for the Treatment of Patients With Chronic Myeloid Leukemia: The 2010 Perspective. Clin Lymphoma Myeloma Leuk 10(Supplement 1):S6-13, 2010. e-Pub 2010. PMID: 20529808.
231. Batty GN, Kantarjian H, Issa JP, Jabbour E, Santos FP, McCue D, Garcia-Manero G, Pierce S, O'Brien S, Cortés JE, Ravandi F. Feasibility of Therapy With Hypomethylating Agents in Patients With Renal Insufficiency. Clin Lymphoma Myeloma Leuk 10(3):205-10, 2010. PMID: 20511166.
232. Jabbour E, Thomas D, Cortes J, Kantarjian HM, O'Brien S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 116(10):2290-300, 2010. e-Pub 2010. PMID: 20209620.
233. Fullmer A, O'Brien S, Kantarjian H, Jabbour E. Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs 15(1):1-11, 2010. PMID: 20055690.
234. Fullmer A, Jabbour E. Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?. Am J Hematol 85(3):158-9, 2010. PMID: 20131307.
235. Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ, Jorgensen JL. Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia 24(3):666-8, 2010. e-Pub 2010. PMID: 20054352.
236. Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W, Kantarjian H. Clofarabine in leukemia. Expert Rev Hematol 3(1):15-22, 2010. PMID: 21082931.
237. Cortes JE, Jones D, O'Brien S,Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28(3):398-404, 2010. e-Pub 2009. PMID: 20008620.
238. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28(3):392-7, 2010. e-Pub 2009. PMID: 20008621.
239. Jabbour E, Hochhaus A, Cortes J, La Rosée P, Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 24(1):6-12, 2010. e-Pub 2009. PMID: 19798095.
240. Jabbour E. Imatinib: High Dose Versus Standard Dose. Clin Adv Hematol Oncol 7(12):812, 2009. PMID: 20332752.
241. Jabbour E, Fava C, Kantarjian H. Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best Pract Res Clin Haematol 22(3):395-407, 2009. PMID: 19959090.
242. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037-43, 2009. e-Pub 2009. PMID: 19567878.
243. Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, Kantarjian HM, Jones D. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 27(22):3642-9, 2009. e-Pub 2009. PMID: 19506164.
244. Fullmer A, O'Brien S, Kantarjian H, Jabbour E. Novel therapies for relapsed acute lymphoblastic leukemia. Curr Hematol Malig Rep 4(3):148-156, 2009. PMID: 20425428.
245. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of achievement of a major cytogenetic response with second generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 113(21):5058-63, 2009. e-Pub 2009. PMID: 19282457.
246. Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing Iron Overload in Patients with Myelodysplastic Syndromes with Oral Deferasirox Therapy. Oncologist 14(5):489-96, 2009. e-Pub 2009. PMID: 19365094.
247. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9):1899-905, 2009. PMID: 19235255.
248. El Kinge AR, Hatoum HA, Mahfouz RA, Otrock ZK, Jabbour E, Kantarjian H, Bazarbachi A. Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia. Leuk Res 33(4):565-6, 2009. e-Pub 2008. PMID: 18571231.
249. Jabbour E, Soverini S. Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia. Semin Hematol 46(2 Suppl 3):S22-6, 2009. PMID: 19621546.
250. Jabbour E, Verstovsek S. Treatment of Myelofibrosis in younger patients: to transplant or not?. Am J Hematol 84(3):131-2, 2009. PMID: 19202548.
251. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113(10):2154-60, 2009. e-Pub 2008. PMID: 19060245.
252. Fava C, Kantarjian H, Cortes J,Jabbour E. Development and targeted use of nilotinib in chronic myeloid leukemia. Drug Des Devel Ther 2:233-43, 2009. e-Pub 2009. PMID: 19920910.
253. Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?. Mayo Clin Proc 84(2):161-9, 2009. PMID: 19181650.
254. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 113(9):1892-8, 2009. e-Pub 2008. PMID: 19109226.
255. Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 4(1):3-10, 2009. e-Pub 2009. PMID: 19343297.
256. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9 Suppl 3:S261-5, 2009. PMID: 19778850.
257. Jabbour E, Cortés JE, Kantarjian H. Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. Clin Lymphoma Myeloma 9 Suppl 3:S272-9, 2009. PMID: 19778852.
258. Fava C, Cortés JE, Kantarjian H, Jabbour E. Standard management of patients with chronic myeloid leukemia. Clin Lymphoma Myeloma 9 Suppl 4:S382-90, 2009. PMID: 20007107.
259. Jones D, Thomas D, Yin CC, O'Brien S, Cortes JE, Jabbour E, Breeden M, Giles FJ, Zhao W, Kantarjian HM. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 113(5):985-94, 2008. e-Pub 2008. PMID: 18615627.
260. Jabbour E Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J.. Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. e-Pub 2008.
261. Rondon G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E.. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution anaylsis. Biol Blood Marrow Transplant 14(8):859-66, 2008.
262. Rondón G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 14(8):859-66, 2008. PMID: 18640568.
263. Jabbour E, El Ahdab S, Cortes J, Kantarjian H. Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opin Investig Drugs 17(7):1127-36, 2008. PMID: 18549348.
264. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112(1):53-5, 2008. e-Pub 2008. PMID: 18403620.
265. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 112(11):2341-51, 2008. PMID: 18398832.
266. Jabbour E, Cortes JE, Kantarjian HM. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer 112(10):2112-8, 2008. PMID: 18348294.
267. Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcome of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood, 2008.
268. Jabbour E, J, Cortes JE, Kantarjian H, Quintas-Cardama A, Radich JP, Bixby DL, Talpaz M, Snead JL, O'Hare T, Eide CA, Deininger MW. Optimizing Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A New Era. Clinical Lymphoma & Myeloma Supplement 8(Supplement 3), 2008.
269. Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 112(5):1089-95, 2008. PMID: 18186499.
270. Jabbour E, Cortés JE, Kantarjian H. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules. Clin Lymphoma Myeloma 8 Suppl 3:S75-81, 2008. PMID: 19254884.
271. Jabbour E, Cortes JE, Ghanem H, O'Brien S, Kantarjian HM. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther 8(1):99-110, 2008. PMID: 18095887.
272. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110(12):4005-11, 2007. e-Pub 2007. PMID: 17785585.
273. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a Phase 2 Study. Cancer 110(9):2012-2018, 2007. PMID: 17849460.
274. Jabbour E, Cortes J, Giles F, Kantarjian H. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer J 13(6):357-65, 2007. PMID: 18032972.
275. Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110(8):2991-2995, 2007. e-Pub 2007. PMID: 17625066.
276. Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 110(6):1295-1302, 2007. PMID: 17623836.
277. Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, Khouri IF. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant 40(5):431-435, 2007. e-Pub 2007. PMID: 17603511.
278. Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs 10(7):468-479, 2007. PMID: 17642017.
279. Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 110(2):340-4, 2007. PMID: 17559140.
280. Mughal T, Cortes J, Cross NC, Donato N, Hantschel O, Jabbour E, Kantarjian H, Melo JV, Skorski T, Silver RT, Goldman JM. Chronic myeloid leukemia--some topical issues. Leukemia 21(7):1347-52, 2007. e-Pub 2007. PMID: 17495971.
281. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109(12):2481-9, 2007. PMID: 17497648.
282. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer 109(11):2171-81, 2007. PMID: 17431887.
283. Jabbour E, Cortes J, Kantarjian H. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?. Oncology (Williston Park) 21(6):653-668, 2007. PMID: 17564324.
284. Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin Investig Drugs 16(5):679-87, 2007. PMID: 17461740.
285. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109(8):3214-8, 2007. e-Pub 2007. PMID: 17209054.
286. Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, Kantarjian H. Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clin Lymphoma Myeloma 7:S51-S57, 2007. PMID: 17382013.
287. Jabbour E, Kantarjian H, Cortes J. Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs 16(3):381-92, 2007. PMID: 17302532.
288. Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109(2):265-73, 2007. PMID: 17133405.
289. Thomas DA, Jabbour E, Kantarjian H, and O'Brien S.. Response: Neurologic toxicity of intrathecal liposomal cytarabine when used for CNS prophylaxis in conjunction with the hyper-CVAD regimen. Blood 110:1698-1699, 2007.
290. Jabbour E, Kantarjian H.. Integrating the new generation of targeted therapies for chronic myelogenous leukemia - Introduction. Seminars in Hematology 44:S1-S3, 2007.
291. Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H. New targeted therapies for chronic myelogenous leukemia: Opportunities to overcome imatinib resistance. Semin Hematol 44(1 Suppl 1):S25-S31, 2007. PMID: 17292738.
292. Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, and Kantarjian H.. Management of patients with newly diagnosed chronic myeloid leukemia: Opportunities and challenges. Clinical Lymphoma & Myeloma 7:S51-S57, 2007.
293. Jabbour E, Kantarjian H. Introduction: chronic myelogenous leukemia (CML). Semin Hematol 44(1 Suppl 1):S1-3, 2007. PMID: 17292735.
294. Jabbour E, Cortes J, Kantarjian H. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol 18(6):578-83, 2006. PMID: 16988578.
295. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10):1767-1773, 2006. e-Pub 2006. PMID: 16855631.
296. Quintas-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Giles F, Ravandi F, Faderl S, Pierce S, Shan J, Verstovsek S, Cortes J. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 107(7):1525-1529, 2006. PMID: 16955510.
297. Kantarjian H,Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat Rev Drug Discov 5(9):717-8, 2006. PMID: 17001803.
298. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 134(1):58-60, 2006. PMID: 16803568.
299. Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, Biron P, Fermé C, Bourhis JH, Vantelon JM, Arnaud P, Ribrag V. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia 20(5):814-819, 2006. PMID: 16511514.
300. Jabbour E, Kantarjian H. Impact of Iron Overload and Transfusion Dependence in Patients With Myelodysplastic Syndromes. Clinical Implications of Anemia 3(1):7-9, 2006.
301. Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome. Cancer 106(5):1090-1098, 2006. PMID: 16435386.
302. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 107(3):880-4, 2006. e-Pub 2005. PMID: 16123215.
303. Quintas-Cardama A, Kantarjian H, Jones D, Talpaz M, Jabbour E, O'Brien S, Luthra R, Wierda W, Nicaise C, and Cortes J.. Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. Journal of Clinical Oncology 24:343S, 2006.
304. Jabbour E, Giles F, Cortes J, O'Brien S, Ravandi F, Borthakur G, Garcia-Manero G, Letvak L, Salvado A, and Kantarjian H.. Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP). Journal of Clinical Oncology 24:358S, 2006.
305. Kantarjian H, Jabbour E, Grimley J, and Kirkpatrick P.. Fresh from the pipeline - Dasatinib. Nature Reviews Drug Discovery 5:717-718, 2006.
306. Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107(2):480-482, 2006. e-Pub 2005. PMID: 16195326.
307. Yee KW, Jabbour E, Kantarjian HM, Giles FJ. Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Ann Hematol 84:18-24, 2005. PMID: 16273408.
308. Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res 11(21):7817-7824, 2005. PMID: 16278404.
309. Oprea C, Cainap C, Azoulay R, Assaf E, Jabbour E, Koscielny S, Lapusan S, Vanel D, Bosq J, Ribrag V. Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. Br J Haematol 131(4):468-471, 2005. PMID: 16281936.
310. Jabbour E, Faderl S, Kantarjian HM. Adult acute Lymphoblastic leukemia. Mayo Clin Proc 80(11):1517-1527, 2005. PMID: 16295033.
311. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 104(3):541-546, 2005. PMID: 15977212.
312. Jabbour E, Peslin N, Arnaud P, Ferme C, Carde P, Vantelon JM, Bocaccio C, Bourhis JH, Koscielny S, Ribrag V. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation. Leuk Lymphoma 46(6):861-867, 2005. PMID: 16019530.
313. Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S. Interferon alpha therapy for patients with essential thrombocythemia - Final results of a phase II study initiated in 1986. Cancer 103(12):2551-2557, 2005. PMID: 15861412.
314. Jabbour E, Giles FJ. New agents in Myelodysplastic syndromes. Curr Hematol Rep 4(3):191-199, 2005. PMID: 15865871.
315. Jabbour E, and Ribrag V.. Acute tumor lysis syndrome: update on therapy. Revue de Medecine Interne 26:27-32, 2005.
316. Jabbour E, Yee K, Giles, F.. FLT-3 receptor tyrosine kinase as a drug target in leukemia. Future Oncology 1:323-333, 2005.
317. Jabbour E, Kantarjian HM, Garcia-Manero G, Issa JP.. Decitabine in myelodysplastic syndromes. Expert Review 2:835-842, 2005.
318. Jabbour E, Kantarjian H, Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: Possible mechanisms of action. Leuk Lymphoma 45(11):2187-2195, 2004. PMID: 15512806.
319. Jabbour E, Keating MJ, Champlin RE, Khouri IF. Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?. Bone Marrow Transplant 34(4):289-297, 2004. PMID: 15220957.
320. Jabbour E, Chalhoub B, Suzan F, Aloulou S, Cainap C, Toumi N, Fermé C, Carde P, Ribrag V. Outcome of elderly patients with aggressive non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: A low probability of cure. Leuk Lymphoma 45(7):1391-1394, 2004. PMID: 15359638.
321. Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Faderl S, Verstovsek S, Ravandi F, Rytting M, Cortes J, Wierda W, Hoshino K, Yang H, Santos-Malave C, Fiorentino J, Jabbour E, Rosner G, and Issa J.P.. Results of a phase I/II study of the combination of 5-aza-2 ' deoxycytidine (DAC) and valproic acid (VPA) in patients (pts) with leukemia. Blood 104:78A-79A, 2004.

Invited Articles

1. Jabbour E. Improving Outcomes of Patients with Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia. The American Journal of Hematology/Oncology V6 No 12 Supplement 14, 2007.
2. Jabbour E, Kantarjian HM. Thrombocytopenia and Myelodysplastic Syndrom: Epidemiology, Clinical Consequences, and Management Approaches. An Expert Column for: MEDSCPAE CME SPECIAL REPORT Evolving Concepts in Thrombocytopenia, 2007.

Editorials

1. Kadia T, Jabbour E, O'Brien S.. Treatment strategies for chronic lymphocytic leukemia. US Oncological Disease, 2006.

Abstracts

1. Prithviraj Bose, Naval Daver, Jabbour E, Allison Pike, Kate J Newberry, Lingsha Zhou, Sherry Pierce, Xuemei Wang, Hagop M. Kantarjian, and Srdan Verstovsek. Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Blood 128(22), 2016.
2. Jabbour E, Kantarjian, H, Thomas, D, Sasaki, K, Ravandi, F, Cortes, J, Pemmaraju, N, Kadia, T, Garris, R, Garcia-Manero, G, Borthakur, G, Wierda, O'Brien, S.. Phase II Study of Combination of Hypercvad with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2014.
3. Jabbour E, O'Brien, S, Sasaki, K, Huang, X, Thomas, D, Rytting, M, Garcia-Manero, G, Cortes, J, Pierce, S, Kadia, T, Kantarjian, H.. Prognostic Factors for Outcome in Patients (pts) with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody. Blood, 2014.
4. Jabbour E, Sasaki, K, Daver, N, Pemmaraju, N, DiNardo, C, Kadia, T, Miller, D, Sukholutsky, V, Huang, X, Borthakur, G, Estrov, Z, Kantarjian, H. Garcia-Manero, G,. Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS). Blood, 2014.
5. Jabbour E, Sasaki, K, Daver, N, Pemmaraju, N, Jain, N, Kadia, T, DiNardo, C, Tuttle, C, Borthakur, G, Konopleva, M, Faderl, S, O’Brien, S, Cortes, J, Kantarjian, H, Garcia-Manero, G.. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. Blood, 2014.
6. Jabbour E, O’Brien, S, Thomas, D, Sasaki, K, Garcia-Manero, G, Ravandi, F, Borthakur, G, York, S, Garris, R, Cortes, J, Kantarjian, H.. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients (≥60 years) with Acute Lymphoblastic Leukemia (ALL). Blood, 2014.
7. Jabbour E, Makenbaeva, D, Lingohr-Smith, M, Lin, J.. Evaluation of Comorbidities Relevant to Tyrosine Kinase Inhibitor Treatment Among Patients with Chronic Myelogenous Leukemia in the U.S. Managed Care Setting. Blood, 2014.
8. Jabbour E, Makenbaeva, D, Lingohr-Smith, M, Lin, Jay. Potential Economic Consequences of Genetic Mutations and Restricted Access to Tyrosine Kinase Inhibitor Treatments Among Patients with Chronic Myelogenous Leukemia in the USA. Blood, 2014.
9. Jabbour E, O’Brien, S, Thomas, D, Sasaki, K, Garcia-Manero, G, Kadia, T, Jain, N, York, S, Garris, R, Cortes, J, Kantarjian, H.. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory/Relapse (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2014.
10. Jabbour E, Kantarjian, H, Thomas, D, Sasaki, K, Garcia-Manero, G, Garris, R, Cortes, J, Kadia, T, Ravandi, F, Verstovsek, S, O’Brien, S.. Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab as Frontline Therapy for Adults with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2014.
11. Jabbour E. Clinical characteristics and outcome of patients (pts) with V299L BCR-ABL kinase domain (kd) mutation after therapy with Tyrosine Kinase Inhibitors (TKIs). Blood, 2008.
12. Jabbour E. Increase in the incidence of Secondary Acute Myeloid Leukemia (2-AML): A single institution experience over 20 years. Blood, 2008.
13. Jabbour E. Long-term efficacy of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in patients (pts) with advanced Chronic Myeloid Leukemia (CML) post imatinib failure. Blood, 2008.
14. Jabbour E. Outcome of patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) post decitabine failure. Blood, 2008.
15. Jabbour E. Results of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for advanced Chronic Myeloid Leukemia (CML) patients (pts) who failed Tyrosine Kinase Inhibitors (TKIs) after developing BCR-ABL kinase domain (kd) mutations. Blood, 2008.
16. Jabbour E. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or accerlerated phase (CML-AP). Blood, 2008.
17. Jabbour E. Combination of the hyperCVAD regimen with dasatinib is effective in patients with relapsed Philadelphia Chromosome (Ph) positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB). Blood, 2008.
18. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112(13):4839-42. e-Pub 2008. PMID: 18818391.
19. Jabbour E. Impact of Imatinib Mesylate Dose Escalation on Resistance and Sub-Optimal Responses to Standard-Dose Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML). Blood, 2007.
20. Jabbour E. Characteristics and Outcome of Patients with Chronic Myeloid Leukemia (CML) and T315I Mutation Following Failure of Imatinib Mesylate Therapy. Blood, 2007.
21. Jabbour E. Clinical Characteristics and Outcome of Patients (pts) with F317L BCR-ABL Kinase Domain (KD) after Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood, 2007.
22. Jabbour E. Event-Free Survival in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with 2nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure is Dependent on the In Vitro Sensitivity of BCR-ABL Kinase Domain (KD) Mutations. Blood, 2007.
23. Jabbour E. In Vitro Response to Sequential Tyrosine Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) Modeled Based on In Vitro Properties of Particular BCR-ABL Kinase Domain (KD) Mutations. Blood, 2007.
24. Jabbour E. Prognostic Significance of Prior Best Response to Imatinib in Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs). Blood, 2007.
25. Jabbour E, Cortes J, Giles F, Kantarjian H.. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer Journal 6:357-65, 2007.
26. DeLima M, Champlin RE, Thall PF, Wang X, Martin TG 3rd, Cook JD, McCormick G, Qazibash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Anderson BS, Patah PA, Caldera Z, Jabbour E, Giralt S.. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia, 2007. e-Pub 2007.
27. Jabbour E, Cortes J, Kantarjian H, Giralt S, Champlin R, and de Lima M.. Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic stem cell transplantation (ASCT) in patients with chronic myeloid leukemia (CML): No evidence for increased transplant-related toxicity. Biology of Blood and Marrow Transplantation 13:91, 2007.
28. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, and de Lima M.. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108:1421-1423, 2006.
29. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, and Garcia-Manero G.. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at MD Anderson Cancer Center. Blood 107:880-884, 2006.
30. Borthakur G, Ravandi-Kashani F, Cortes J, Jabbour E, Faderl S, O'Brien S, Verstovsek S, Garcia-Manero G, Newman BA, Giles F, Issa JP, and Kantarjian H.M.. Decitabine induces responses in patients with myelodysplastic syndrome (MDS) after failure of azacitidine therapy. Blood 108:157A, 2006.
31. Jabbour E, Jones D, Kantarjian H, O'Brien S, Garcia-Manero G, Giles F, Wierda W, and Cortes J.. Dynamics of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia (CML) after treatment with one, two or three tyrosine kinase inhibitors (TKI). Blood 108:225A, 2006.
32. Giles F, Borthakur G, Ravandi F, Verstovsek S, Pierce S,Jabbour E Cortes J, and Kantajian H.. Comorbidity scoring using the hematopoetic cell transplantation comorbidity index (HCTCI) is predictive of early death rate and event free survival (EFS) in patients over 60 years of age receiving induction therapy for acute mycloid leukemia (AML). Blood 108:559A, 2006.
33. Jabbour E, Kantarjian H, Abruzzo L, Giles F, Rios MB, and Cortes J.. Chromosomal abnormalities in Philadelphia chromosome (Ph)-negative metaphases appearing during novel tyrosine kinase inhibitors (NTKI) therapy in patients (pts) with chronic myeloid leukemia (CML) after imatinib-failure. Blood 108:600A, 2006.
34. Jabbour E, Kantarjian H, Ravandi-Kashani F, Garcia-Manero G, O'Brien S, and Cortes J.. Clinical significance of loss of chromosome Y (-Y) in patients with chronic myeloid leukemia (CML): Is it clonal evolution?. Blood 108:600A, 2006.
35. Atallah E, Durand JB, Kantarjian H, Jabbour E, O'Brien S, Rios MB, and Cortes J.. Congestive heart failure is a rare event in patients (pts) receiving imatinib therapy. Blood 108:609A, 2006.
36. Jabbour E, Kantarjian H, Giles F, O'Brien S, and Cortes J.. . Treatment with nilotinib for patients with chronic myeloid leukemia (CML) who failed prior therapy with imatinib and dasatinib. Blood 108:616A, 2006.
37. Jabbour E, Cortes J, Giles F, O'Brien S, Letvak L, and Kantarjian H.. Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP). Blood 108:616A, 2006.
38. Jabbour E, Kantarjian H, Jones D, Giles F, Borthakur G, O'Brien S, and Cortes J.. Clinical characteristics and outcome of patients (pts) with T315I mutation after imatinib failure. Blood 108:621A, 2006.
39. Jabbour E, Kantarjian HM, Cortes J, Wierda WG, Ferrajoli A, Faderl S, O'Brien S, Ravandi-Kashani F, Verstovsek S, Garcia-Manero G, Davisson J, Giles F, Shan J, and Issa J.P.. Survival benefit with decitabine compared to historical experience with intensive chemotherapy in patients with higher risk myelodysplastic syndrome (MDS). Blood 108:749A-750A, 2006.
40. Jabbour E, O'Brien S, Ravandi-Kashani F, Cortes J, Borthakur G, Verstovsek S, Garcia-Manero G, Giles F, Zanoria L, Davisson J, Issa JP, and Kantarjian H.M.. Decitabine induces high response rates in patients with chronic myelomonocytic leukemia (CMML). Blood 108:750A, 2006.
41. Jabbour E, Kantarjian H, Koller CA, Faderl S, Ferrajoli A, Richie MA, Garcia-Manero G, Cortes J, Estrov Z, Ravandi-Kashani F, Giles F, and Verstovsek S.. PEG-Intron therapy in patients with Philadelphia chromosome-negative myeloproliferative disorders (MPD): Final result of a phase II study. Blood 108:1039A, 2006.
42. Jabbour E, Cortes J, Kantarjian H, Giralt S, Giles F, Anderson BS, Champlin R, and de Lima M.. Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic stem cell transplantation (ASCT) in patients with chronic myeloid leukemia (CML): No evidence for increased transplant-related toxicity. Blood 108:407B, 2006.
43. Champlin RE, Jabbour E, Cortes J, Kantarjian H, Anderson BS, Giralt S, and de Lima M.. Treatment of patients (pts) with chronic myeloid leukemia (CML) and imatinib failure after developing BCR-ABL kinase mutations with allogeneic stem cell transplantation (ASCT). Journal of Clinical Oncology 24:348S, 2006.
44. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, and Issa J.P.. Phase 1/2 study of the combination of 5-aza-2 '-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279, 2006.
45. Jabbour E, Cortes J, de Lima M, Anderson B, Giralt S, Kantarjian H, and Champlin R.. Treatment of patients (pts) with chronic myeloid leukemia (CML) and imatinib failure after developing Bcr-Abl kinase mutations with allogeneic stem cell transplantation (ASCT). Biology of Blood and Marrow Transplantation 12:18, 2006.
46. Jabbour E, Hosing C, Pro B, Khouri I, Younes A, Champlin R, and Fayad L.. Pre-transplant positive pet/gallium scans predict poor outcome in relapsed/refractory hodgkin lymphoma (HL). Biology of Blood and Marrow Transplantation 12:114-115, 2006.
47. Jabbour E, Kantarjian H, O'Brien S, Verstovsek S, Garcia-Manero G, Rios MB, and Cortes J.. Chromosomal abnormalities in Philadelphia chromosome (Ph)-negative metaphases appearing during imatinib mesylate (IM) therapy in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase. Blood 106:317A-318A, 2005.
48. Jabbour E, Cortes J, Talpaz M, Jones D, O'Brien S, Nicaise C, and Kantarjian H.. Correlation of clinical response to dasatinib (BMS-354825) with BCR-ABL mutation status in imatinib-resistant patients (pts) with chronic myeloid leukemia (CML) treated at MD Anderson cancer center (MDACC). Blood 106:318A, 2005.
49. Jabbour E, Kantarjian H, Talpaz M, Jones D, O'Brien S, Giles F, Garcia-Manero G, Ravandi F, Faderl S, Verstovsek S, Rios MB, and Cortes J.. Outcome of salvage therapy in patients (pts) with chronic myeloid leukemia (CML) who failed imatinib after developing BCR-ABL kinase mutation. Blood 106:318A, 2005.
50. Jabbour E, Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Garcia-Manero G, Wierda W, Pierce S, Shan JQ, and Estey E.. Results of intensive chemotherapy in 998 patients aged 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome. Blood 106:525A, 2005.
51. Jabbour E, Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan JQ, Plunkett W, Keating M, and Estey E.. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Blood 106:710A, 2005.
52. Jabbour E, Hosing C, Pro B, Khouri I, and Fayad L.. Positive pre-transplant PET/GA67 scan (GA) predicts poor outcome in refractory and relapse Hodgkin's lymphoma (HL). Annals of Oncology 16:121, 2005.
53. Jabbour E, Hosing C, Pro B, Champlin R, Khouri I, Romaguera J, and Fayad L.E.. Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin's lymphoma (HL). Journal of Clinical Oncology 23:562S, 2005.
54. Jabbour E, Kantarjian H, Jones D, O'Brien S, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, and Cortes J.. Long-term incidence and outcome of BCR-ABL mutations in patients (pts) with chronic myeloid leukemia (CML) treated with imatinib mesylate - P-loop mutations are not associated with worse outcome. Blood 104:288A, 2004.
55. Oki Y, Jabbour E, Kantarjian H, Estey E, Cortes JE, Faderl S, Pierce S, Zhou X, Bekele BN, and Garcia-Manero G.. Intracranial hemorrhage (ICH) in patients (pts) with newly diagnosed leukemia: Incidence and effect on outcome. Blood 104:216B, 2004.
56. Jabbour E, Kantarjian H, Verstovsek S, Jones D, O'Brien S, Luthra R, Ravandi-Kashani F, Wierda W, Giles F, Rios MB, and Cortes J.. Imatinib mesylate for patients (pts) with hypereosinophilic syndrome (HES) and systemic mastocytosis (SM): A phase II trial. Blood 104:271B, 2004.
57. Jabbour E, Verstovsek S, Gandhi V, Cortes J, Giles F, Koller C, O'Brien S, Plunkett W, Garcia-Manero G, Jackson E, Kantarjian H, and Andreeff M.. 2 chlorodeoxyadenosine (2-CdA) and cytarabine (ara-C) combination is effective and safe in idiopathic hypereosinophilic syndrome (HES). Blood 104:274B, 2004.
58. Jabbour E, Peslin N, Sebban C, Patte C, Gargi T, Ferme C, Bourhis JH, Vantelon JM, Arnaud P, and Vincent R. High survival rate with modified LMT-81 regimen in lymphoblastic lymphoma (LL). Blood 102:405A, 2003.
59. Jabbour E, Peslin N, Arnaud P, Carde P, Vantelon JM, Bocaccio C, Ferme C, Bourhis JH, and Vincent R.. Prognostic value of IPI assessed before high dose salvage therapy in chemosensitive relapsed aggressive lymphomas (NHL). Blood 102:481B, 2003.

Book Chapters

1. Jabbour E, Faderl S, Kantarjian H.. Adult acute lymphocytic leukemia. In: The MD Anderson manual of clinical oncology. Kantarjian H, Koller C, Wolff R (Eds.),. McGraw-Hill: New York, 2016.
2. Jabbour E, Cortes J, Kantarjian H.. Targeted therapy in cancer: chronic myeloid leukemia. In: Targeted therapy in cancer. Razelle Kurzrock and Maurie Markman (Eds),. The Humana Press: New Jersey, 2016.
3. Jabbour E, Cortes J, Kantarjian H.. Chronic myeloid leukemia: new targeted therapies. In: Recent advances in the chronic myeloproliferative disorders. Tariq Mughal and John Goldman (Eds),. Taylor and Francis: New York, 2015.
4. Jabbour E, Kantarjian H, Cortes J.. Chronic myeloid leukemia: frontline-current treatment options. In: Recent advances in the chronic myeloproliferative disorders. Tariq Mughal and John Goldman (Eds),. Taylor and Francis: New York, 2013.
5. Jabbour E, Estey E, Kantarjian HM. Adult acute Myeloid Leukemia. In: Mayo Clin Proc. 2, 15-32, 2006.